An active murine–human chimeric Fab antibody derived from Escherichia coli, potential therapy against over-expressing VEGFR2 solid tumors

Biotechnological Products and Process Engineering

DOI: 10.1007/s00253-011-3335-y

Cite this article as:
Huang, J., Liang, J., Tang, Q. et al. Appl Microbiol Biotechnol (2011) 91: 1341. doi:10.1007/s00253-011-3335-y


Many recombinant murine monoclonal antibodies (mAbs) were studied under pre-clinical or clinical development and became one of the most prolific drug classes in oncology. Vascular endothelial growth factors receptor 2 (VEGFR2) has been implicated to play an important role in tumors. We have established a murine anti-VEGFR2 mAb. To reduce the shortcoming of the mAb, a murine–human chimeric Fab (cFab) named FA8H1 was constructed with gene engineering techniques and expressed as a soluble and functional protein in Escherichia coli Top10F′. Several immunological methods were used to characterize the cFab, including ELISA, affinity and kinetics assay, IP, IF, FACS, and IHC. The results illuminated that cFab maintained the specificity for the VEGFR2 antigen. The active cFab also effectively identified VEGFR2 over-expressing cells in a number of archived human cancer tissues, compared to its parental antibody. The FA8H1 provided the basis for potential therapy research against over-expressing VEGFR2 human solid tumors.


VEGFR2 Chimeric Fab Immunological method Escherichia coli 

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.Department of PathologyAffiliated Hospital of Nantong UniversityNantongChina
  2. 2.Huadong Medical Institute of BiotechniquesNanjingChina
  3. 3.Cancer Center and Department of Pathology, Key Laboratory of Antibody Technique of the Ministry of HealthNanjing Medical UniversityNanjingChina

Personalised recommendations